Bevacizumab Combined With Cisplatin Plus Pemetrexed as Front-line Chemotherapy for Asymptomatic Brain Metastases in Non-squamous Non-small Cell Lung Cancer.
- Conditions
- on-squamous Non-small Cell Lung Cancer
- Registration Number
- JPRN-UMIN000008811
- Lead Sponsor
- Hanshin Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 35
Not provided
1)Interstitial pneumonia or pulmonary fibrosis detectable on CT scan 2)History of severe drug allergy 3)History of active infection or other serious disease condition (GI bleeding,etc.) 4)History of poorly controlled pleural effusion,pericardial effusion and ascites 5)History of severe heart disease(uncontrollable arrythmia,uncontrollable angina pectoris,herat failure,etc.) 6)Uncontrollable hypertension 7)Uncontrollable diabetes mellitus 8)Hystory of active double cancer 9)Invasion to main blood vessels 10)History of active psychological disease 11)Severe hemoptysis or blood sputum 12)History of gastrointestinal perforation 13)Symptomatic or more than 2 cm diameter brain metastases 14)Uncured bone fracture (excluding compression fracture due to osteoporosis) 15)Planned surgery 16)Obvious cavity on pulmonary lesions. 17)Bleeding tendency 18)Uncontrolled thromboembolizm 19)Pregnancy 20)Participation in the trial is judged to be inappropriate by the attending doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-free survival
- Secondary Outcome Measures
Name Time Method 1. Overall survival 2. Response rate 3. Disease control rate 4. Progression free survival, response rate, and disease control rate of brain metastases 5. Safety